Martin Pass named chief development officer at Amphista

Thursday 13 January 2022
Amphista Therapeutics Ltd
Appointee name
Martin Pass

United Kingdom

Martin Pass, a former AstraZeneca Plc executive, has joined Amphista Therapeutics Ltd as chief development officer to lead work on targeted protein degradation. Prior to AstraZeneca, he was a medicinal chemist at GlaxoSmithKline Plc. He holds a PhD in organic chemistry from Imperial College London, UK and did post-doctoral research at the University of Virginia, US.

Amphista Therapeutics announced the appointment on 6 December 2021.

Copyright 2022 Evernow Publishing Ltd